Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m. Eastern Time and will be accessible live via Vanda's website under the Investors tab.
Investors are advised to register at the conference site at least 15 minutes early to download required software; an archived link will be available on Vanda's site for approximately 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – VNDA
In the Feb 27 session, VNDA gained 3.60%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | BLA acceptance | Positive | +1.4% | FDA accepted imsidolimab BLA for treating generalized pustular psoriasis. |
| Feb 20 | FDA approval | Positive | +41.5% | FDA approved BYSANTI for bipolar I disorder and schizophrenia in adults. |
| Feb 11 | Earnings results | Negative | -17.6% | 2025 results showed revenue growth but a large net loss and tax allowance. |
| Feb 04 | Earnings date | Neutral | -4.9% | Company scheduled Q4 and full-year 2025 results release and call details. |
| Jan 08 | Regulatory setback | Negative | -14.1% | FDA said HETLIOZ sNDA for jet lag disorder cannot be approved as submitted. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VNDA news shows price generally tracking the tone of fundamental FDA and earnings events, with mostly aligned reactions to both positive approvals and negative regulatory outcomes.
Over the last few months, Vanda has reported several major milestones. On Feb 20, 2026, the FDA approved BYSANTI (milsaperidone), driving a 41.49% gain. On Feb 25, 2026, the FDA accepted the BLA for imsidolimab in GPP, with shares up 1.35%. Earlier, full-year 2025 results on Feb 11 highlighted $216.1M in revenue but a $220.5M net loss, followed by a -17.63% move. A negative FDA decision letter on HETLIOZ sNDA on Jan 8 coincided with a -14.05% decline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The corporate presentation given at the Citizens Life Sciences Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations. A link to the archived conference will be available on Vanda's website for a period of approximately 30 days.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-in-the-2026-citizens-life-sciences-conference-302699013.html
SOURCE Vanda Pharmaceuticals Inc.